Abstract: Influenza pandemics are an on-going threat for the human population as the avian influenza viruses H5N1 and H7N9 continue to circulate in the bird population and the chance of avian to human transmission increases. Neuraminidase, a glycoprotein located on the surface of the influenza virus, plays a crucial role in the viral replication process and hence, has proven to be a useful target enzyme for the treatment of influenza infections. The discovery that certain subtypes of influenza neuraminidase have an additional cavity, the 150 cavity, near the substrate binding site has triggered considerable interest in the design of influenza inhibitors that exploit this feature. Currently available antiviral drugs, neuraminidase inhibitors oseltamivir and zanamivir were designed using crystal structures predating this discovery by some years. This mini review is aimed at summarizing our group's efforts, together with related work from other groups, on neuraminidase inhibitors that are designed to exploit both the catalytic site and the 150 cavity. The design of a parent scaffold that yields a potent inhibitor which is active in cell culture assays and retains activity against several neuraminidases from mutant strains is also described. Finally, the role of serendipity in the discovery of a new class of potent neuraminidase inhibitors with a novel spirolactam scaffold is also highlighted. D r a f t
Introduction
Influenza infection, caused by influenza viruses A and B, is a respiratory illness characterized by symptoms such as fever, cough, sore throat, weakness and general discomfort. 1 However, the severity of the illness varies significantly depending on the circulating virus and the age and health status of the host. 1 Different strains of influenza virus A are distinguished and characterized by the distinct antigenic properties of two major surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA). 1 Each plays an important and distinct role in the influenza infection cycle. HA mediates the initial attachment of the virus particles to the host cell by interacting with terminal sialic acid residues of the host cell-surface glycans. 2 NA plays a role at a later stage in the infection cycle, it helps the virus to spread from the infected host cell. 3 The budding virions from the infected host cells tend to aggregate on the host cell surface due to the interaction of HA and sialic acid residues present in the cell surface glycan structures. NA, characterized as a sialidase biochemically, cleaves these sialic acid residues and facilitates the release of the newly formed virions from the infected host cell and is thus responsible for Considering the present-day scenario with changes in the population density and significant increase in air travel, the magnitude of impact could be significantly higher in case of a pandemic outbreak although public health awareness and preparedness have improved significantly.
To date, 18 subtypes of HA and 10 subtypes of NA have been characterized. Among those, 16 subtypes of HA (H1-H16) and 9 subtypes of NA (N1-N9) have been found circulating in birds and H17, H18 and N10 have been found circulating in bats. 1, 6 Until 2003, the human population was only exposed to three HA (H1, H2 and H3) subtypes and two NA subtypes (N1 people died from H5N1-infection or subsequent other infections, about 53% of the total infected cases worldwide. 7 With the first outbreak in early 2013, the world has recently witnessed a total of 5 intermittent epidemic outbreaks of another avian influenza virus, H7N9 that infected humans with a high mortality rate of 30%. 8 In the case of both H5N1 and H7N9 outbreaks, the disease was reported to be contracted by handling infected poultry (bird-to-human transmission).
Although human-to-human transmission has not been reported for these avian viruses, a growing concern is that the possibility of genetic reassortment between avian influenza viruses, H5N1 and H7N9 and any of the previously circulating human influenza viruses H1N1, H2N2 and H3N2
could result in a new, highly-virulent strain with the capability of efficient human-to-human transmission.
Annual vaccination offers protection only against previously circulated strains of influenza viruses and will not be effective against infections that are caused by new strains causing the seasonal epidemic or pandemic outbreaks. Owing to its critical role in the viral replication process, neuraminidase has been studied extensively and is a proven target in the treatment of influenza disease. In fact, neuraminidase inhibitors, oseltamivir (1) 9 and zanamivir (2), 10 are the two block-buster antiviral drugs that have been stockpiled by health authorities throughout the world as part of their pandemic preparedness (Chart 1). Peramivir (3, Chart 1) 11 is another neuraminidase inhibitor that was recently approved for the treatment of influenza disease. 12 However, we note that the efficacy of using neuraminidase inhibitors in the treatment or prevention of influenza infections has been questioned. 13 A major challenge in the field of antiviral therapy is the development of drug-resistant mutations in the target enzyme and influenza neuraminidase is clearly not an exception. For example, isolation of an oseltamivirresistant H5N1 avian influenza virus from a patient indicated viral resistance to these drugs may be increasing. 14 Hence, there exists a constant need for the search for novel antiviral drugs to overcome the multi drug-resistant mutant influenza strains, with the hope that a multi-drug approach will compromise the virus, as with HIV-1 infection. 15 There has been tremendous amount of research focused on the development of neuraminidase inhibitors. In this mini review, we aim to cover recent progress in our own laboratory, together with related work from other groups, with a special focus on a group of neuraminidase inhibitors designed to exploit a newly discovered additional pocket near the active sites of neuraminidase, known as the 150 cavity.
We describe also the design of a parent scaffold that yields a potent inhibitor which is active in cell culture assays and retains activity against several neuraminidases from mutant strains.
Finally, the role of serendipity in the discovery of a potent neuraminidase inhibitor with a novel spirolactam scaffold is described. 
Neuraminidase crystal structures and the 150 cavity
All known 9 subtypes of neuraminidase are phylogenetically classified into 2 groups. Subtypes N1, N4, N5 and N8 belong to group 1 and N2, N3, N6, N7 and N9 belong to group 2.
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Determination of three-dimensional crystal structures of N2 and N9 subtypes from group 2, reported in 1983 3c and 1987, 17 respectively, marked an important milestone in influenza antiviral therapy and greatly facilitated rational drug design. The active site of neuraminidase with highly conserved active-site amino acid residues across all subtypes has been divided into three binding pockets. Pocket 1, composed of residues E276, E277, R292 and N294, interacts with the glycerol side chain of sialic acid. Pocket 2 is composed of hydrophobic residues such as A246, I222, and R224 side chain and interacts with the methyl group of the N-acetyl moiety. Pocket 3 is the largest of the three pockets and is formed by many polar residues such as E119, E227, and D151.
Structure-based drug design using these crystal structures led to the discovery of oseltamivir (1) and zanamivir (2) . In the absence of crystal structures of group 1 enzymes, a similar catalytic site architecture across all 9 subtypes was assumed, based on the observation that the crystal 
Extension of oseltamivir structure to incorporate 150 cavity binders
The design and syntheses of a series of oseltamivir analogues to target both the 150 cavity and catalytic site were first reported by our group (3-9, Scheme 1). 22 Since the newly found 150 cavity adjoins the catalytic cavity, we simply extended the structure of oseltamivir by attaching suitable 150 cavity binders using triazole as a linker. Closer inspection of the open loop crystal structure of the N9-oseltamivir complex revealed that the C-5 position with the amino group is suitably positioned towards the 150 cavity and hence was chosen as our modification site. The decision to include a variety of lipophilic groups of different sizes, ranging from simple alkyl chains to a complex steroid moiety, as our potential 150 cavity binders was based on the ensemble-based virtual screening by others. 23 In these computational studies, fragments identified with high affinity scores for the 150 cavity are found to be mainly lipophilic in nature.
Using triazole as a linker allowed us to gain rapid access to different target compounds starting from one key azido intermediate via copper-catalyzed azide-alkyne cycloaddition (CuAAC) of various alkynes carrying potential 150 cavity filling groups. The key azide intermediate 10 was
synthesized from D-(-)-quinic acid by following conceptually similar synthetic strategies used in the oseltamivir synthesis. 21 We also synthesized the double bond regioisomer of oseltamivir, isooseltamivir 11, 24 as a parent compound en route to the triazole-extended oseltamivir analogues. 22 Key intermediate 10 was also used to synthesize a novel guanidine compound which turned out to be a potent inhibitor with activity against several mutant strains. 22 Results pertaining to this new candidate are discussed in detail in section 5 (see later).
Inhibitory activities of compounds 3-9 against virus-like particles (VLPs) containing a neuraminidase with influenza A/N1 activity ranged from K i values of 0.07 to 11 µM ( Table 1) .
The K i values of iso-oseltamivir (11, Scheme 1) and zanamivir were determined to be 1.5 and 0.16 nM, respectively, under these assay conditions. To gain more evidence that our compounds indeed access the 150 cavity for binding, the most active compound in the series, compound 4 with a K i = 70 nM against the N1 containing VLPs (group 1) was screened against N2 (group 2)
subtype that was shown to be devoid of this 150 cavity by X-ray crystallography. 22 As expected, compound 4 was found to be 37-fold less active against the N2 subtype, with a K i value of 2.6
µM. The observed 37-fold selectivity for group 1 enzyme (N1) over group 2 enzyme (N2)
together with results from a saturation transfer difference (STD) NMR experiment with compound 4 and N1 containing VLPs allowed us to conclude that the triazole-extended portion of these molecules indeed makes contacts with the 150 cavity of the receptor molecule. 22 Sialic acid-based inhibitors such as zanamivir (2) show cross reactivity with some isoforms of the human neuraminidases (hNEU); 25 however, triazole-extended oseltamivir analogues 3-9 did not
show significant off-target inhibition against two human neuraminidases, NEU3 and NEU4. 26 However, despite the potent inhibitory activity observed in the functional assay using N1
containing VLPs (K i = 72 nM for the lead compound 4), the triazole series did not show significant inhibitory activities at concentrations below 500 µM in the influenza A virus replication inhibition assay performed using two strains (H1N1, Puerto Rico/8/32 and H3N2, Hong Kong/1/68). 27 Although this proof-of-concept series performed as we anticipated and provided a lead compound 4 with nanomolar activity, it still required further optimization to improve its efficacy in cell-based assays.
Scheme 1. Synthesis of the first series of neuraminidase inhibitors with 150 cavity binders.
22 Table 1 . Inhibitory activities of compounds 3-9, 11 and zanamivir against N1-containing VLPs To gain further insights into their binding mode, we obtained crystal structures of N8 in complex with three of the triazole-extended inhibitors 3-5 and the parent compound 11. 28 These structures ( Figure 2 ) confirmed that indeed the 150 cavity is occupied and thus provided experimental validation of our design principle. In all three N8-inhibitor complexes, the binding mode of the cyclohexene ring and the interactions in the active site cavity were quite similar to those of the parent compound 11. 28 However, the triazole portion of the inhibitors adopts two distinct binding modes depending on the substituent at the C-4 position of the triazole ring ( Figure 2 ). In the N8:3 complex with the 1-hydroxypropyl substituent, the triazole ring is oriented in such a way that the three nitrogen atoms are facing towards the base of the cavity.
Surprisingly, this binding mode allowed the 150-loop to close around the triazole group, a feature that was not expected when 150 cavity is occupied. On the other hand, in the N8:4 and N8:5 complexes, the triazole ring is rotated by approximately 135° compared to the N8:3 complex and consequently, the branched alcohol substituents of the triazole ring extend into the 150 cavity. Despite having similar binding modes in the catalytic cavity as that of the parent D r a f t compound 11, reduced inhibitory activities for the triazole-extended oseltamivir analogues in the influenza A virus replication inhibition assay suggested that the new interactions gained within the 150-loop and cavity do not fully compensate for the strong hydrogen bonding network that was compromised by the installation of the less basic triazole ring in place of the parent amino group. 28 This observation was corroborated by the long-term molecular dynamics (MD) simulation study, performed by us, which suggested that the 150 cavity filling group is not stable in the 150 cavity but exits the cavity periodically, thus affecting the overall binding affinity. We therefore designed and synthesized the second-generation inhibitors 12 and 13 in which we shifted the triazole extension to the C-6 position in the oseltamivir scaffold (Scheme 2). 30 The rationale for this design was two-fold: (i) to restore the missing hydrogen bond network D r a f t 13 with D151 and E119 residues by keeping an intact amino (12) or guanidino group (13) at C-5 and (ii) to exploit the 150 cavity with the triazole-extension for new interactions. As opposed to our first-generation inhibitors, the second-generation inhibitors have the double bond in the same place as in oseltamivir, which makes them true oseltamivir analogues. We have utilized the azide intermediate 10 from the first series for the synthesis of second-generation inhibitors 12 and 13.
Target compounds were synthesized using dihydroxylation, azidation of the allyl acetate via allylic azide [3,3]-sigmatropic rearrangement, and copper-catalyzed azide-alkyne cycloaddition as key steps (Scheme 2).
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As conjectured, the second-generation triazole-extended oseltamivir analogues (12 and 13) showed better inhibitory effects in the virus replication inhibition assay compared to the firstgeneration inhibitors (3-9). When screened against H3N2 (Hong Kong/1/68) strain, compounds 12 and 13 showed inhibitory effects at 100 µM and 20 µM, respectively. two types of H9N2-NAs screened, suggesting that these compounds were utilizing both the catalytic site and 150 cavity for binding. Docking studies also corroborated the binding pose for these compounds, which snuggly fit across both sites. Importantly, compound 25 was ~8-fold and ~3-fold more active than oseltamivir (1) and the guanidine analogue of oseltamivir (24), respectively. However, as with oseltamivir, compound 25 showed ~1000-fold decrease in inhibitory activity against H5N1-NA carrying the oseltamivir-resistant H274Y mutation (IC 50 for 25 = 1.16 µM and IC 50 for oseltamivir = 2.1 µM). 31 On the other hand, compound 26 was found to be less affected by the H274Y mutation compared to compound 25 and oseltamivir. The IC 50
value of compound 26 against the H274Y-mutant was determined to be 160 nM, that is, less than 80-fold decrease in inhibitory activity compared to the wild-type inhibition. Clearly, these results suggest that exploitation of the 150 cavity is a viable strategy in the search for next-generation neuraminidase inhibitors. Despite the success in accessing both catalytic site and 150 cavity, there was no increase in the inhibitory activity of 32 compared to the parent compound DANA (33). Subsequent work to improve this scaffold using substituted aromatic moieties or bulky aliphatic groups at the terminal position of the C-3 allyl extension (35-43, Chart 5) was not successful and resulted in compounds with either comparable or weaker inhibitory activities to that of 32. 35 Rudrawar et al., 36 also reported an interesting study in which they synthesized amino (44) and guanidino (45) derivatives of compound 32 (Chart 5) and tested them against an atypical group 1 enzyme (N1 from pdm09-H1N1), and a group 2 enzyme (N2 from pdm57-H2N2), which were shown to lack the 150 cavity by crystallography. Both amino derivative 44 and the parent compound 32
showed comparable inhibitory activities (IC 50 = 3.5 and 6.5 µM, respectively) against N1 sialidase (pdm09 H1N1). Compound 32 was previously shown to inhibit other group 1 enzymes with a 150 cavity at a similar level. 34 However, guanidine substitution (45) values of 2.3 and 2.9 nM against N1 and N2, respectively. 39 We also note that compound 49 is the most active compound discovered to date among the zanamivir-based neuraminidase inhibitors that are designed to target both the catalytic site and 150 cavity. 
Discovery of carba-zanamivir and a novel spirolactam scaffold
In the discovery process of zanamivir (1), guanylation of the 4-amino derivative of DANA (50) resulted in 100-fold increase in the inhibitory activity. 10 The K i value for zanamivir with a guanidine group at C-4 (zanamivir numbering) was 0.1 nM whereas the parent compound, the 4-amino derivative of DANA had a K i value of 10 nM. 10 However, in the case of oseltamivir (1) guanylation of the C-5 amino group 51 (oseltamivir numbering) didn't have a significant effect and showed only a 5-fold increase in activity (IC 50 value 1 nM vs 0.2 nM). 24 We hypothesized that in the case of zanamivir, the increase in inhibitory activity upon guanylation could be due to the position of the double bond that is different from oseltamivir. Hence, we decided to utilize the key azido intermediate 10, 22 used in the synthesis of our first generation 150 cavity inhibitors, to derive a carbocyclic analogue of zanamivir (52) In the functional assay using VLPs containing N1 activity, compound 52 exhibited comparable inhibitory activity (K i = 0.46 nM) to that of zanamivir (K i = 0.16 nM). 22 It also D r a f t showed excellent inhibitory activity in the influenza virus replication assay against two strains H3N2 (Hong Kong/1/68) and H1N1 (Puerto Rico/8/32). 27 Similar to standard inhibitors oseltamivir and zanamivir, compound 52 inhibited both strains at less than µM concentrations. It also exhibited very high selectivity for viral neuraminidases over human neuraminidases. 26 When tested for the off-target effect of this compound against human sialidases, isoforms NEU3 and NEU4. compound 52 didn't show measurable inhibition below 1 mM concentrations against these human sialidases. This selectivity is crucial for any anti-viral agent to avoid adverse side effects resulting from potential off-target inhibition of human neuraminidases which recognize similar substrates.
Significantly, the hybrid inhibitor 52 showed reduced susceptibility to the oseltamivirresistant H274Y mutation. 28 The mechanism of oseltamivir resistance by H274Y mutation was well established by crystallographic studies. 40 The H274Y mutation confers changes in the lipophilic pocket that interacts with the 3-pentlyoxy side chain of oseltamivir and consequently the pentyloxy group shifts 2 Aº out of the enzyme active site which, in turn, makes other groups around the cyclohexene ring shift from their optimal positions. Peramivir (3), having a 3-pentyl sidechain is also affected by this mutation (100-fold). 41 When screened against A/Brisbane/59/2007 (oseltamivir-sensitive, wild-type), the hybrid inhibitor 52 exhibited a lower D r a f t 26 The crystal structure of N8 in complex with the hybrid inhibitor 28 and MD-simulations 29 provided explanations for the observed potent inhibitory activity of this compound and its reduced susceptibility towards H274Y mutation. Examination of the crystal structure of the N8:52 complex indicated that the overall binding mode and the interactions of the groups around the cyclohexene ring with the active site residues generally overlay very well with the N8:
oseltamivir complex ( Figure 5 ). 28 The guanidine group adopts a similar position as seen in the N8: zanamivir complex and makes additional hydrogen bond interactions with carboxyls of E119
and E227 and the backbone carbonyls of W178 and D151. Such a strong hydrogen-bond network surrounding the guanidino group in addition to the usual interaction of the carboxylate moiety with the arginine triad seem to anchor the hybrid inhibitor in the active site. Based on these observations and our MD-simulation studies, we proposed that the hybrid inhibitor can pivot about these two-anchoring points in response to a H274Y mutation without lifting the entire ligand out of the active as opposed to what was seen in the oseltamivir case, thus explaining its reduced susceptibility towards H274Y mutation. We note, however, that the reduced susceptibility of 52 towards H274Y mutation is not just the effect of guanylation alone because the guanidine derivative of oseltamivir 51 was found to be sensitive to the H274Y mutation to the same extent as oseltamivir. 42 Therefore, it is the combined effect of both change in position of the double bond relative to oseltamivir and the guanidine function which allows this new scaffold to overcome the H274Y mutation.
A B D r a f t When screened against drug-resistant mutations in the N2 subtype, compound 52 continued to maintain a better inhibitory profile than oseltamivir. 43 The due to the loss of a salt bridge with D151 and the amino group. In the case of compound 52, the salt bridge is retained between guanidine and E227 and D151 residues, thus explaining the better inhibitory activity of this compound compared to oseltamivir against these mutations ( Figure   6 ). 43 Furthermore, compound 52 also showed potent inhibition of neuraminidases from H7N9
and H1N1 strains with comparable IC 50 values to that of oseltamivir and zanamivir (Table 2) . 44, 45 Thus, the hybrid inhibitor 52 has an excellent inhibitory profile against a panel of influenza neuraminidases and remains resilient towards drug-resistant mutations both in N1 and N2 subtypes ( Table 2 ) which makes it an ideal candidate for further optimization. During the course of further optimization of the lead compound 52, we serendipitously discovered a novel spirolactam scaffold with potent neuraminidase inhibitory activity. 47 Our original intention was to synthesize the isothiourea version (53) of the hybrid inhibitor 52. The synthetic approach to this target compound involved nucleophilic ring opening of the N-Acetyl D r a f t aziridine intermediate 54 using Boc-protected thiourea, followed by hydrolysis of the methyl ester and deprotection of the Boc-protecting group, as shown in Scheme 6. However, we isolated two diastereomeric spirolactams 55 and 56 instead of the desired target compound 53. We have explained the formation of this spirolactam ring from the coupled product 58 via base-catalyzed double bond migration followed by lactamization, facilitated by the conditions employed in the ester hydrolysis step (Scheme 7). 47 Significantly, the spirolactam 55 was found to be a potent inhibitor of influenza virus replication with an effective concentration as low as 10 -6 -10
against H3N2 (Hong Kong/1/68) strain. However, it required 100 times higher concentration to be effective against the H1N1 (Puerto Rico/8/32) strain. This compares well with the inhibitory activity of the hybrid inhibitor 52 against these two strains (effective concentration was as low as 8 × 10 -8 and 2 × 10 -6 M, respectively). The diastereomeric spirolactam 56 was found to be less active than 55. X-ray crystallographic analysis of N8 in complex with 55 and 56 provided better understanding of the molecular basis behind the observed differences in the inhibitory activities. 47 The overall binding mode of both compounds and interactions within the active site were very similar, except for the difference in the orientation of the spirolactam ring. In the case of the N8: 55 complex, the interactions between the spirolactam ring and the enzyme appeared to be influenced by the zwitterionic resonance state (55a) adopted by the thiazolidinone ring.
Stabilizing interactions between the iminium nitrogen and the acidic patch (E119, E227, E277) and a water-mediated hydrogen bond favouring the negative charge build up at the amide nitrogen create a favorable placement for the thiazolidinone ring within the active site and thus contribute to the potency of this compound (Figure 7a ). However, in the case of spirolactam 56, the orientation of the thiazolidinone ring is less favorable because it forces the carbonyl group D r a f t 31 into the acidic patch (E119, E227, E277), leading to electrostatic repulsion and thus affecting the inhibitor binding to the enzyme active site (Figure 7b ). 
